Home » News » Clinical Intelligence » Regeneron/Bayer reveal positive results for CRVO study

Regeneron/Bayer reveal positive results for CRVO study

Friday, April 29, 2011

Regeneron Pharmaceuticals and Bayer HealthCare reveal positive results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the phase III GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO). 

In GALILEO, the primary endpoint at week 24 was achieved: 60.2% of patients receiving monthly VEGF Trap-Eye 2 milligrams gained at least 15 letters of vision from baseline, compared to 22.1% of patients receiving sham injections (p

The most common adverse events were those typically associated with intravitreal injections or the underlying disease.  The incidence of ocular serious adverse events was higher in the sham group compared to the active treatment arm (8.8% versus 2.9%).

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!